secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103526
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027
------------------------------------------------------------------------

- Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.
- Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.
- SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.
- Fast Track designation granted by FDA for bempikibart in alopecia areata.
- Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/0000950170-25-103526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/qttb-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer